Skip to main content

Gilotrif Side Effects

Generic name: afatinib

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 5, 2024.

Note: This document contains side effect information about afatinib. Some dosage forms listed on this page may not apply to the brand name Gilotrif.

Applies to afatinib: oral tablet.

Serious side effects of Gilotrif

Along with its needed effects, afatinib (the active ingredient contained in Gilotrif) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking afatinib:

More common

Less common

Rare

Get emergency help immediately if any of the following symptoms of overdose occur while taking afatinib:

Symptoms of overdose

Other side effects of Gilotrif

Some side effects of afatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to afatinib: oral tablet.

Gastrointestinal

Very common (10% or more): Diarrhea (96%), stomatitis (71%), cheilitis (12%), nausea, vomiting

Common (1% to 10%): Dyspepsia

Uncommon (0.1% to 1%): Pancreatitis[Ref]

Dermatologic

Very common (10% or more): Acneiform rash/dermatitis (90%), paronychia (58%), dry skin (31%), pruritus (21%), alopecia (13%)

Common (1% to 10%): Palmar-plantar erythrodysesthesia syndrome, nail disorders

Uncommon (0.1% to 1%): Bullous, blistering, and exfoliating lesions

Rare (0.01% to 0.1%): Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)[Ref]

Genitourinary

Very common (10% or more): Cystitis (13%)[Ref]

Hepatic

Very common (10% or more): Alanine aminotransferase increased (11%)

Common (1% to 10%): Aspartate aminotransferase increased[Ref]

Metabolic

Very common (10% or more): Decreased appetite (29%), weight decreased (17%)

Common (1% to 10%): Dehydration, hypokalemia[Ref]

Ocular

Very common (10% or more): Conjunctivitis (11%)

Common (1% to 10%): Dry eye

Uncommon (0.1% to 1%): Keratitis (e.g., acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye)[Ref]

Other

Very common (10% or more): Fatigue (19%), pyrexia (12%)[Ref]

Respiratory

Very common (10% or more): Epistaxis (17%), nasopharyngitis (14%), rhinorrhea (11%)

Uncommon (0.1% to 1%): Interstitial lung disease (ILD) or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, alveolitis allergic)[Ref]

Musculoskeletal

Common (1% to 10%): Muscle spasm[Ref]

Psychiatric

Very common (10% or more): Insomnia (15%)[Ref]

Nervous system

Very common (10% or more): Headache (14%), dizziness (11%)

Common (1% to 10%): Dysgeusia[Ref]

Renal

Common (1% to 10%): Renal impairment/renal failure[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Gilotrif (afatinib). Boehringer Ingelheim. 2013.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.